Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × OTHER_GOV × elbasvir-grazoprevir drug combination × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C 1 Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 2 Irinotecan 2 Carboplatin 2 pertuzumab 1 ledipasvir 1 genexol-PM 1 elbasvir-grazoprevir drug combination 1 dolutegravir 1 apatinib 1 Vinorelbine 1 Trastuzumab 1 Tissue Banks 1 Tai Ji 1 Sofosbuvir 1 S 1 (combination) 1 Ritonavir 1 Ribavirin 1 Radiotherapy, Intensity-Modulated 1 Qigong 1 Physical Examination 1 Oxaliplatin 1 Nucleosides 1 Nivolumab 1 Magnesium 1 Levoleucovorin 1 Interleukin-2 1 Immunotherapy 1 Immune Checkpoint Inhibitors 1 Hydralazine 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04546802 2020-09-14

HATCHeT

Bayside Health

Phase 3 Withdrawn

Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡